Generic DEXCHLORPHENIRAMINE MALEATE INN entry, drug patent and freedom to operate

Sponsor	Phase
EMS	Phase 3
Mantecorp Industria Quimica e Farmaceutica Ltd.	Phase 3

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	POLMON	dexchlorpheniramine maleate	SYRUP;ORAL	202520-001	Jul 16, 2018		RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Schering	POLARAMINE	dexchlorpheniramine maleate	TABLET;ORAL	086835-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Schering	POLARAMINE	dexchlorpheniramine maleate	SYRUP;ORAL	086837-001	Jul 19, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Ani Pharms	DEXCHLORPHENIRAMINE MALEATE	dexchlorpheniramine maleate	TABLET;ORAL	088682-001	Jan 17, 1986		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 4, 2026

Dexchlorpheniramine maleate is a mature, low-cost first-generation antihistamine with limited commercial growth potential. Its market is fragmented across generic prescription products and country-specific branded formulations, including Polaramine in several markets. The drug has no meaningful remaining U.S. market exclusivity, faces competition from chlorpheniramine and newer nonsedating antihistamines, and has limited public revenue visibility because manufacturers generally do not report product-level sales.

What is the current market position of dexchlorpheniramine maleate?

Dexchlorpheniramine maleate is the dextrorotatory form of chlorpheniramine, an H1 histamine receptor antagonist used to treat allergic rhinitis, conjunctivitis, urticaria, angioedema, and related allergic symptoms. It is commonly supplied as immediate-release tablets, extended-release tablets or capsules, and oral liquid formulations.[1]

The product is commercially mature. Its market position is based on:

Long clinical history and established physician familiarity.
Low manufacturing complexity.
Availability in multiple oral dosage forms.
Continued demand in countries where older antihistamines remain routinely prescribed or dispensed.
Low prices relative to newer second-generation antihistamines.

Its disadvantages are sedation, impaired alertness, anticholinergic effects, and a less favorable tolerability profile than cetirizine, loratadine, desloratadine, and fexofenadine. The FDA labeling for dexchlorpheniramine warns about drowsiness and additive central nervous system depression with alcohol or sedatives.[1]

What dosage forms are commercially relevant?

Dosage form	Typical strength	Commercial role
Immediate-release tablet	2 mg	Core generic prescription format
Extended-release tablet or capsule	4 mg	Differentiated legacy formulation
Oral solution or syrup	Varies by market	Pediatric and swallowing-related use
Combination products	Market-specific	Allergy, cold, or cough positioning

The extended-release format has greater formulation value than the immediate-release tablet because it can support differentiated dosing and product positioning. Its commercial value remains constrained by the availability of inexpensive alternatives and the age of the underlying technology.

How large is the dexchlorpheniramine maleate market?

Public sources do not provide a reliable, standalone global revenue figure for dexchlorpheniramine maleate. Manufacturers typically aggregate sales within broader allergy, cough-and-cold, or generic pharmaceutical segments. Market-research estimates also vary substantially depending on whether they include chlorpheniramine, combination products, branded products, hospital channels, and non-U.S. markets.

The market is best characterized as:

A small molecule with broad geographic availability.
A mature generic category.
A low-average-selling-price product.
A fragmented market with limited supplier concentration.
A market with low probability of material unit or price expansion.

In the United States, the product competes in a prescription antihistamine segment that has been displaced in many allergy indications by newer agents. In Latin America, parts of Asia, and selected European and Middle Eastern markets, branded dexchlorpheniramine products may retain stronger visibility.

Which companies sell dexchlorpheniramine maleate?

The commercial supplier base changes by jurisdiction and over time. It includes:

Generic prescription manufacturers.
Regional pharmaceutical companies.
Contract manufacturers and local marketing authorization holders.
Brand owners or licensees using the Polaramine name outside the United States.
Retail and hospital suppliers that purchase through pharmaceutical wholesalers.

A definitive global company ranking is not available from public regulatory filings. U.S. product availability should be verified through FDA Drugs@FDA, the Orange Book, and current DailyMed entries rather than relying on historical brand ownership.[2][3]

What is the FDA regulatory status of dexchlorpheniramine maleate?

Dexchlorpheniramine maleate is an established FDA-regulated drug substance with approved oral prescription formulations. Its regulatory profile is mature rather than developmental.

The principal U.S. regulatory characteristics are:

Regulatory factor	Status
FDA pathway	Established prescription-drug pathway
Active ingredient	Dexchlorpheniramine maleate
Primary indication	Relief of allergic symptoms
Dosage forms	Tablets, extended-release products, and oral liquids depending on product
Controlled-substance status	Not a controlled substance
Pediatric use	Product- and age-specific labeling applies
Generic pathway	Abbreviated New Drug Application pathway is available where reference products and product-specific requirements permit
Biosimilar pathway	Not applicable

Current labeling must be assessed product by product because inactive ingredients, concentrations, age restrictions, and dosage instructions differ among manufacturers.[1]

What is the Orange Book status of dexchlorpheniramine maleate?

The Orange Book identifies FDA-approved prescription drug products and, where applicable, therapeutic-equivalence ratings and patent or exclusivity information.[2] Dexchlorpheniramine products are generally relevant to the generic approval system rather than to an active innovator exclusivity strategy.

The commercial implications are:

Generic approval is the dominant U.S. regulatory model.
An applicant may rely on an approved reference product through an ANDA.
Product-specific labeling and bioequivalence requirements remain relevant.
Historical patents associated with older branded products do not normally create a current barrier unless a live, listed patent remains in force.

Orange Book status can change when products are withdrawn, discontinued, delisted, or reclassified. A live commercial assessment therefore requires product-level review of current listings.

What patents protect dexchlorpheniramine maleate?

The active ingredient is an old antihistamine, and composition-of-matter protection has expired. No commercially meaningful U.S. exclusivity should be expected from the active pharmaceutical ingredient itself.

Potential historical patent categories include:

Composition patents covering dexchlorpheniramine or related antihistamine chemistry.
Salt or crystalline-form claims.
Extended-release dosage forms.
Controlled-release matrices.
Combination products.
Method-of-use claims for allergic conditions.
Manufacturing and purification processes.

For a mature product, these categories generally have limited present-day value because the relevant patent terms would have begun decades ago. Current risk is more likely to arise from a formulation-specific patent or a jurisdiction-specific product right than from a basic molecule patent.

When does dexchlorpheniramine maleate lose exclusivity?

The meaningful loss of exclusivity occurred long ago. The drug is commercially post-exclusivity in the United States and major regulated markets.

Exclusivity category	Current commercial assessment
Composition-of-matter exclusivity	Expired
New chemical entity exclusivity	Expired
Original branded-product exclusivity	Expired
Immediate-release formulation protection	Historical or expired in ordinary circumstances
Extended-release protection	Historical claims may exist, but broad market protection is not expected
Pediatric exclusivity	Not a current commercial barrier
Orphan exclusivity	Not applicable to the core product
Biosimilar exclusivity	Not applicable

An exact patent expiration date cannot be assigned to the global product because protection varied by country, product, dosage form, and historical patent family. The active ingredient’s commercial exclusivity, however, is not a current market feature.

Are there Paragraph IV challenges involving dexchlorpheniramine maleate?

Paragraph IV litigation is unlikely to be a significant current market factor for standard dexchlorpheniramine products. Paragraph IV challenges are most commercially important when an ANDA applicant seeks to invalidate or avoid a listed patent covering a high-value branded product.

Dexchlorpheniramine lacks the revenue profile that usually supports prolonged Hatch-Waxman litigation. The likely U.S. entry model is routine generic approval after review of:

Reference-listed-drug status.
Therapeutic-equivalence requirements.
Bioequivalence.
Product-specific guidance.
Current Orange Book patent listings.
Manufacturing and labeling compliance.

Historical litigation may exist around legacy branded products or related antihistamine formulations, but it should not be treated as a current barrier without a live patent and an active commercial reference product.

What formulation patents protect dexchlorpheniramine maleate?

Formulation protection is the most plausible residual intellectual-property category, particularly for extended-release products and combination formulations. The commercial value of such patents depends on whether the formulation delivers a clinically relevant advantage and whether generic applicants can design around the claims.

Relevant formulation issues include:

Release rate and duration.
Matrix composition.
Particle size and dissolution profile.
Liquid stability.
Preservative systems.
Palatability and pediatric acceptability.
Combination with decongestants or other allergy agents.
Manufacturing controls required to reproduce the pharmacokinetic profile.

Immediate-release dexchlorpheniramine tablets are difficult to differentiate through formulation alone. Extended-release products may have greater technical barriers, but the market opportunity is smaller and generic substitution remains a major constraint.

What method-of-use patents cover dexchlorpheniramine maleate?

Method-of-use patent value is limited because dexchlorpheniramine has been used for standard allergy indications for many years. Potential claims could cover:

Specific allergic conditions.
Age-defined patient populations.
Dosing schedules.
Combination treatment.
Symptom-specific use.
Reduced-sedation or modified-delivery regimens.

Broad claims for allergic rhinitis, urticaria, or allergic conjunctivitis are unlikely to provide meaningful current exclusivity. Any remaining value would depend on narrow claims, enforceability, and whether the indication is carved out of generic labeling.

How strong is the dexchlorpheniramine maleate patent estate?

The patent estate is weak as a platform for exclusivity but adequate for low-cost generic commercialization.

Patent-estate factor	Assessment
Core molecule protection	Very weak or expired
Broad indication protection	Weak
Immediate-release formulation protection	Weak
Extended-release technology	Potentially stronger but likely historical
Manufacturing know-how	Moderate operational value
Trade secrets	Possible, but limited strategic differentiation
Freedom-to-operate risk	Generally low for ordinary products
Litigation exposure	Low relative to branded specialty drugs

The principal barriers are regulatory execution, product quality, manufacturing economics, and distribution rather than patents.

What is the competitive landscape for dexchlorpheniramine maleate?

Dexchlorpheniramine competes against both pharmacologic substitutes and other products containing the same active ingredient.

How does dexchlorpheniramine compare with other antihistamines?

Drug	Generation	Sedation risk	Typical market position
Dexchlorpheniramine	First	Relatively high	Mature prescription or regional branded product
Chlorpheniramine	First	Moderate to high	Low-cost generic and combination-product market
Cetirizine	Second	Lower, but possible	Broad allergy market
Loratadine	Second	Low	Large OTC and generic market
Fexofenadine	Second	Low	Premium nonsedating allergy segment
Desloratadine	Second	Low	Branded and generic allergy segment

Newer antihistamines have stronger consumer recognition, broader OTC distribution in many markets, and better daytime-use profiles. Dexchlorpheniramine retains relevance where price, physician familiarity, availability, or local brand strength outweigh sedation concerns.

What is the financial trajectory for dexchlorpheniramine maleate?

The financial trajectory is mature to declining in developed markets, with stable or modest growth possible in selected emerging markets. The product does not have the characteristics of a high-growth pharmaceutical asset.

Revenue drivers

Population growth in markets where older antihistamines remain common.
Seasonal allergy prevalence.
Regional brand recognition.
Availability of pediatric liquid formulations.
Hospital and institutional purchasing.
Continued use in combination cold-and-allergy products.
Low-cost access in price-sensitive markets.

Revenue pressures

Generic price erosion.
Substitution by loratadine, cetirizine, and fexofenadine.
Sedation and anticholinergic concerns.
Reduced use in older adults.
Retail preference for newer OTC antihistamines.
Product discontinuations caused by low margins.
Limited ability to raise prices without losing volume.

Financial metric	Expected trajectory
Unit demand	Stable to declining in mature markets
Net price	Downward pressure
Gross margin	Moderate for efficient manufacturers; weak for small-volume suppliers
Brand premium	Available only in selected regional markets
R&D return	Low for conventional formulations
Licensing value	Limited unless tied to a strong regional brand or delivery technology
Acquisition value	Usually portfolio-based rather than product-based
Revenue concentration	Often dispersed across multiple generic suppliers

The product can generate useful cash flow for a manufacturer with an established supply chain, but it is unlikely to support a standalone growth thesis. Commercial value is higher when dexchlorpheniramine is sold as part of a broader allergy, respiratory, or pediatric portfolio.

What licensing deals affect dexchlorpheniramine maleate?

Licensing activity is more likely to involve regional trademarks, distribution rights, or combination products than the underlying molecule. A commercially relevant deal would typically transfer:

A national or regional brand.
Marketing authorization.
Manufacturing rights.
A pediatric formulation.
An extended-release product.
A fixed-dose combination.
Distribution rights through pharmacies or hospitals.

The lack of active composition patents reduces the value of conventional patent royalties. Licensing economics are therefore driven by regulatory registrations, brand recognition, distribution access, and manufacturing cost.

What manufacturing and IP barriers exist?

Manufacturing barriers are operational rather than fundamental. Dexchlorpheniramine maleate is a conventional small molecule that can be produced by established pharmaceutical manufacturers. The critical controls include:

Assay and impurity control.
Content uniformity.
Dissolution performance.
Stability of oral liquids.
Microbial control for liquid products.
Extended-release reproducibility.
Packaging that preserves product stability.
Compliance with current good manufacturing practices.

For extended-release products, dissolution and release-profile reproducibility can create a greater regulatory hurdle than the active ingredient itself. For immediate-release tablets, manufacturing scale and procurement efficiency are more important than proprietary technology.

What generic entry risks exist for dexchlorpheniramine maleate?

Generic entry risk is already realized rather than prospective. The main commercial risk is continued price competition among existing suppliers.

A new entrant would likely face:

Limited achievable pricing.
Small market size in the United States.
Established alternatives with stronger demand.
Potentially thin wholesaler margins.
Seasonal volume variability.
Regulatory and supply-chain costs disproportionate to revenue.
Difficulty securing durable differentiation.

A generic entrant may still succeed with a low-cost manufacturing base, a differentiated liquid or extended-release product, or distribution in markets where dexchlorpheniramine remains widely prescribed.

What is the geographic coverage of the market?

Dexchlorpheniramine is sold under different regulatory and commercial conditions across jurisdictions.

Region	Market characteristics
United States	Mature prescription generic market; limited standalone growth
Europe	Country-specific availability; stronger substitution by second-generation agents
Latin America	Regional brands and combination products can remain important
Asia	Variable prescription, pharmacy, and OTC status
Middle East and Africa	Demand depends on local registration and distributor access
Emerging markets	Greater opportunity for low-cost products, but pricing and registration barriers remain

Market authorization, dispensing status, brand ownership, and product availability must be assessed at the country level.

Key Takeaways

Dexchlorpheniramine maleate is a mature first-generation antihistamine with limited growth potential.
Its U.S. market is primarily generic and post-exclusivity.
Core molecule, broad indication, and conventional immediate-release formulation protection are not meaningful current barriers.
Extended-release and liquid formulations may offer technical differentiation, but their commercial value is limited.
The main competitive threat comes from cetirizine, loratadine, fexofenadine, and other second-generation antihistamines.
Public companies generally do not disclose standalone dexchlorpheniramine revenue.
Financial performance depends on manufacturing cost, regional brands, distribution, and portfolio economics.
Paragraph IV litigation and biosimilar risk are not significant current drivers.
The best commercial opportunities are low-cost supply, regional licensing, pediatric formulations, and selected emerging markets.

FAQs

Is dexchlorpheniramine maleate still profitable?

It can remain profitable for efficient generic manufacturers, but margins are constrained by low prices, fragmented demand, and competition from other antihistamines. It is more valuable as part of a broader product portfolio than as a standalone growth asset.

Is dexchlorpheniramine maleate available over the counter?

Its regulatory status varies by country and formulation. In the United States, conventional products have primarily been marketed as prescription drugs, while other countries may permit pharmacy or OTC sale of selected products.

Does dexchlorpheniramine maleate have patent protection?

The active ingredient’s original patent protection has expired. Any current protection would most likely relate to a specific formulation, combination, manufacturing process, or narrow method of use.

Can a company launch a generic dexchlorpheniramine liquid?

A company may be able to launch a generic liquid if it satisfies the applicable regulatory pathway, reference-product requirements, bioequivalence or comparative testing standards, stability requirements, and manufacturing controls.

Is dexchlorpheniramine maleate a biosimilar opportunity?

No. Dexchlorpheniramine maleate is a chemically synthesized small molecule. Generic-drug pathways, not biosimilar pathways, apply.

References

U.S. Food and Drug Administration. (n.d.). DailyMed: Dexchlorpheniramine maleate prescribing information. National Library of Medicine. https://dailymed.nlm.nih.gov/
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
World Health Organization Collaborating Centre for Drug Statistics Methodology. (n.d.). ATC/DDD index: Antihistamines for systemic use. https://www.whocc.no/atc_ddd_index/

US Patents:	0
Tradenames:	3
Applicants:	4
NDAs:	5
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	56
Clinical Trials:	5
Patent Applications:	1,928
What excipients (inactive ingredients) are in dexchlorpheniramine maleate?	dexchlorpheniramine maleate excipients list
DailyMed Link:	dexchlorpheniramine maleate at DailyMed

Dexchlorpheniramine maleate - Generic Drug Details

What are the generic drug sources for dexchlorpheniramine maleate and what is the scope of freedom to operate?

Summary for dexchlorpheniramine maleate

Recent Clinical Trials for dexchlorpheniramine maleate

Anatomical Therapeutic Chemical (ATC) Classes for dexchlorpheniramine maleate

US Patents and Regulatory Information for dexchlorpheniramine maleate

# Dexchlorpheniramine Maleate Market Dynamics, Patent Status, Competition, and Financial Trajectory